Can Immunotherapy Eliminate Rectal Cancer?
Can Immunotherapy Eliminate Rectal Cancer? The Growing Role of Genetic Testing in Treatment Decisions
Why Rectal Cancer Treatment Is Changing
For many years, rectal cancer treatment followed a standard approach that usually involved surgery, chemotherapy, and radiation therapy. Although these treatments continue to save lives, doctors now understand that every rectal cancer behaves differently.
Recent advances in cancer genetics have shown that the biological makeup of a tumor can influence how it responds to treatment. Because of this, oncologists are increasingly using genetic and molecular testing to design treatment plans tailored to each patient.
At Ravi's American Cancer Care, Vijayawada, comprehensive cancer evaluation includes advanced molecular diagnostics that help identify treatment opportunities beyond conventional therapies.
How Immunotherapy Works
The human immune system constantly searches for abnormal cells and destroys them. However, some cancer cells develop mechanisms that allow them to avoid immune detection and continue growing.
Immunotherapy is designed to help the immune system recognize these hidden cancer cells and attack them more effectively. Rather than directly killing cancer cells like chemotherapy, immunotherapy enhances the body's natural defense mechanisms.
This approach has produced encouraging results in specific groups of rectal cancer patients.
Why Immunotherapy Is Effective Only for Certain Tumors
Not all rectal cancers respond in the same way to immunotherapy.
The effectiveness of treatment often depends on whether the tumor contains certain genetic abnormalities. Two important biomarkers that oncologists commonly evaluate are:
- Microsatellite Instability-High (MSI-H)
- Deficient Mismatch Repair (dMMR)
These markers provide valuable information about how a tumor behaves and whether immunotherapy may be beneficial.
Understanding MSI-High Tumors
Every cell in the body must copy its DNA accurately when it divides. Normally, repair systems identify and correct errors that occur during this process.
In some cancers, these repair mechanisms become defective. As mistakes accumulate, the tumor develops a large number of genetic alterations.
When these changes become extensive, the tumor may be classified as MSI-High.
Tumors with high levels of genetic instability often produce abnormal proteins that make them easier for immune cells to recognize. This characteristic is one reason why immunotherapy may be particularly effective in some MSI-High cancers.
What Does dMMR Mean?
Mismatch repair proteins act as quality-control systems for DNA.
When these proteins stop functioning properly, genetic mistakes remain uncorrected and continue to accumulate over time. This condition is known as Deficient Mismatch Repair, commonly abbreviated as dMMR.
Many dMMR tumors also demonstrate MSI-High characteristics. Because these cancers contain numerous genetic abnormalities, they may be more likely to respond to immune-based treatments.
Why Genetic Testing Matters
In the past, treatment decisions were based mainly on imaging studies and tumor staging.
Today, cancer specialists also examine the molecular profile of the tumor. This additional information helps determine whether advanced treatment options such as immunotherapy should be considered.
Testing may include:
- MSI Analysis
- MMR Protein Evaluation
- Next Generation Sequencing (NGS)
- Comprehensive Molecular Profiling
Without proper molecular testing, doctors may not be able to identify the most suitable treatment options for a patient.
Can Immunotherapy Completely Remove Rectal Cancer?
Research in recent years has generated significant excitement among cancer specialists worldwide.
Clinical studies have shown that some patients with locally advanced MSI-High or dMMR rectal cancer experienced complete clinical responses after immunotherapy. In these cases, follow-up examinations did not detect active tumor tissue.
For certain patients, immunotherapy has shown promising outcomes and may become an important part of treatment.
However, it is important to remember that:
- Every rectal cancer is different.
- Most tumors are not MSI-High.
- Not all patients qualify for immunotherapy.
- Treatment decisions require expert evaluation.
For this reason, personalized assessment remains essential before selecting any treatment strategy.
The Importance of NGS Testing
Next Generation Sequencing (NGS) is an advanced testing method that helps doctors identify important genetic changes within a tumor.
This technology can identify important genetic changes involving genes such as:
- KRAS
- NRAS
- BRAF
- HER2
- Other clinically relevant biomarkers
The information obtained through NGS helps oncologists make informed decisions regarding targeted therapies, immunotherapy options, and long-term management plans.
Exploring Organ Preservation Strategies
In the past, surgery was often a key part of rectal cancer treatment.
With improvements in systemic therapies and molecularly guided treatment, some patients who achieve excellent responses may be considered for organ-preservation approaches under strict medical supervision.
These decisions require:
- Detailed imaging assessment
- Careful patient selection
- Regular surveillance
- Long-term follow-up
The goal is always to maintain cancer control while preserving quality of life whenever appropriate.
What Is Liquid Biopsy?
Liquid biopsy is an innovative diagnostic tool that detects circulating tumor DNA (ctDNA) from a blood sample.
This technology may help oncologists evaluate:
- Response to treatment
- Presence of residual disease
- Early signs of recurrence
- Future monitoring strategies
Because it requires only a blood sample, liquid biopsy offers a less invasive method for ongoing cancer surveillance.
Precision Oncology: A Personalized Approach
Cancer treatment is increasingly moving toward precision oncology, where therapies are selected based on the unique genetic characteristics of an individual's tumor.
This approach may involve:
- Molecular profiling
- Advanced genomic testing
- NGS analysis
- Immunotherapy assessment
- Liquid biopsy monitoring
- Personalized treatment planning
By understanding the biology of a tumor, oncologists can develop more targeted treatment strategies rather than relying solely on traditional treatment pathways.
Frequently Asked Questions
Do all rectal cancer patients qualify for immunotherapy?
No. Immunotherapy may benefit only certain rectal cancer patients, depending on the genetic and molecular features of their tumor.
How can doctors identify suitable candidates for immunotherapy?
Specialized tests including MSI analysis, MMR testing, and genomic profiling help determine whether immunotherapy may be beneficial.
What is the significance of dMMR in rectal cancer?
dMMR indicates a defect in the DNA repair system, resulting in increased genetic mutations that may enhance responsiveness to immunotherapy.
Why is NGS testing recommended?
NGS provides detailed information about genetic alterations within a tumor, helping guide personalized treatment decisions.
Can surgery always be avoided if immunotherapy works?
Treatment recommendations vary from patient to patient. Decisions regarding surgery depend on tumor response, imaging findings, clinical evaluation, and specialist assessment.
Looking Ahead
The discovery of MSI-High and dMMR tumors has significantly changed the way rectal cancer is evaluated and treated. These biomarkers have helped identify patients who may benefit from innovative therapies that were not available a decade ago.
As molecular diagnostics, genomic testing, liquid biopsy, and immunotherapy continue to evolve, cancer care is becoming increasingly personalized, helping oncologists deliver treatments that are better aligned with each patient's individual disease characteristics.
Advanced Cancer Care in Vijayawada
Ravi's American Cancer Care
Located on Kaleswara Rao Road, opposite Pushpa Hotel Bus Stop, Suryaraopeta, Vijayawada – 520002.
+91 8889996108
Available Services
- Rectal Cancer Evaluation
- Molecular Profiling
- MSI Testing
- MMR Testing
- NGS Testing
- Liquid Biopsy
- Immunotherapy Assessment
- Personalized Cancer Treatment Planning